Strategic partnerships HbO2 Therapeutics already collaborates with academic and staffing networks to expand access pathways, presenting an opportunity to partner with hospitals, veterinary clinics, and blood banks to pilot Expanded Access programs and extend Hemopure and Oxyglobin utilization.

Regulatory pathways With Oxyglobin approved for canine anemia and Hemopure available under investigational status in the US, there is potential to pursue regulatory-friendly partnerships and reimbursement strategies that accelerate clinical access in markets with established FDA/EMA frameworks.

Vet and human markets Dual product portfolio serving human and veterinary needs creates cross-market sales angles; targeting veterinary specialty networks and human trauma/aseptic transfusion alternatives could unlock revenue from both sectors.

Evidence and adoption Public filings signaling an IPO and ongoing collaboration with major medical centers suggest momentum; leverage investor interest to attract tiered customers, academic sites, and early adopter hospitals for real-world data and expanded access programs.

Global expansion Existing international approvals (South Africa, Russia) coupled with UMCG collaboration indicates a pathway to broaden geographic reach; identify regional distributors and regulatory consultants to accelerate market entry in underserved regions.